A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants

NCT ID: NCT02758392

Last Updated: 2017-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-30
• Study Completion Date: 2017-01-31

Brief Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants.

Detailed Description

This is a randomized, double-blind, placebo-controlled, single ascending dose, single site, interventional study. There will be 5 single ascending dose (SAD) IV cohorts and 1 SC cohort. Nine participants will be enrolled into each of 5 IV cohorts and 1 SC cohort and participants will be randomized at a ratio of 2:1 to receive JNJ-61178104 or placebo. The total duration of participants participation will be approximately 21 weeks including a Screening Visit up to 4 weeks prior to study drug administration. Participants will have an inpatient period consisting of 6 days/5 nights and will return to the study-site at Weeks 2, 3, 4, 5, 7, 9, 13, and 17. Participants will be evaluated for safety throughout the study.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Dose 1: JNJ-61178104 OR Placebo IV

Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.

Group Type: EXPERIMENTAL

JNJ-61178104 Intravenous

Intervention Type: DRUG

Participants will receive JNJ-61178104 Intravenously on Day 1.

Placebo

Intervention Type: DRUG

Participants will receive placebo on Day 1.

Dose 2: JNJ-61178104 OR Placebo IV

Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.

Group Type: EXPERIMENTAL

JNJ-61178104 Intravenous

Intervention Type: DRUG

Participants will receive JNJ-61178104 Intravenously on Day 1.

Placebo

Intervention Type: DRUG

Participants will receive placebo on Day 1.

Dose 3: JNJ-61178104 OR Placebo IV

Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.

Group Type: EXPERIMENTAL

JNJ-61178104 Intravenous

Intervention Type: DRUG

Participants will receive JNJ-61178104 Intravenously on Day 1.

Placebo

Intervention Type: DRUG

Participants will receive placebo on Day 1.

Dose 4: JNJ-61178104 OR Placebo IV

Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.

Group Type: EXPERIMENTAL

JNJ-61178104 Intravenous

Intervention Type: DRUG

Participants will receive JNJ-61178104 Intravenously on Day 1.

Placebo

Intervention Type: DRUG

Participants will receive placebo on Day 1.

Dose 5: JNJ-61178104 OR Placebo IV

Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.

Group Type: EXPERIMENTAL

JNJ-61178104 Intravenous

Intervention Type: DRUG

Participants will receive JNJ-61178104 Intravenously on Day 1.

Placebo

Intervention Type: DRUG

Participants will receive placebo on Day 1.

Dose 6: JNJ-61178104 OR Placebo SC

Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.

Group Type: EXPERIMENTAL

JNJ-61178104 Subcutaneous

Intervention Type: DRUG

Participants will receive JNJ-61178104 Subcutaneously on Day 1.

Placebo

Intervention Type: DRUG

Participants will receive placebo on Day 1.

Interventions

JNJ-61178104 Intravenous

Participants will receive JNJ-61178104 Intravenously on Day 1.

Intervention Type: DRUG

JNJ-61178104 Subcutaneous

Participants will receive JNJ-61178104 Subcutaneously on Day 1.

Intervention Type: DRUG

Placebo

Participants will receive placebo on Day 1.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study
• Participant must have a body weight in the range of 50 Kilogram (kg) to 100 kg, inclusive, and have a body mass index of 19 Kilogram per meter square (kg/m^2) to 30 kg/m2, inclusive
• Participant must be healthy on the basis of clinical laboratory tests performed at Screening and Day-1. If the results of the serum chemistry panel including liver enzymes, hematology panel, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's medical record with documented review confirmation by the investigator
• Before randomization, a woman must not be of childbearing potential: a) Postmenopausal {greater than (>) 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level >40 International Units Per Litre (IU/L) at Screening}; or b) Permanently sterilized (example, bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, oophorectomy); or c) Otherwise be incapable of pregnancy
• Be considered eligible according to the following tuberculosis (TB) Screening criteria: a) Have no history of latent or active TB prior to Screening; b) Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination; c) Have had no recent close contact with a person with active TB; d) Have a negative T-Spot TB test result at Screening

Exclusion Criteria

• Participant currently has or has a history of any clinically significant medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, cardiac, vascular, metabolic, endocrine, rheumatologic, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
• Participant has a QT corrected according to Fridericia's formula (QTcF) interval >450 msec, has a complete left or right bundle branch block, or has a history or current evidence of additional risk factors for torsades de pointes (example, heart failure, hypokalemia, family history of Long QT Syndrome) at Screening and at Day -1
• Participant has had major surgery, (example, requiring general anesthesia) within 4 months before Screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 17 weeks after the last dose of study drug administration
• Participant plans to undergo non-major elective surgery within 4 weeks prior to study drug administration through the end of the study
• Participant has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or to any components of the formulation of JNJ-61178104 and its excipients used in this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Merksem, , Belgium

Countries

Belgium

Other Identifiers

61178104NAP1001

Identifier Type: OTHER

Identifier Source: secondary_id

2015-004253-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CR108162

Identifier Type: -

Identifier Source: org_study_id